ZBH Stock Chart & Stats
CHF78.50
-CHF2.50(-3.85%)
At close: 4:00 PM EDT
CHF78.50
-CHF2.50(-3.85%)
Day’s Range― - ―
52-Week RangeCHF62.50 - CHF119.00
Previous CloseN/A
Volume4.00
Average Volume (3M)0.00
Market Cap
CHF15.21B
Enterprise ValueCHF23.68K
Total Cash (Recent Filing)CHF410.00M
Total Debt (Recent Filing)CHF7.48B
Price to Earnings (P/E)24.1
Beta0.21
Next Earnings
Nov 04, 2026EPS Estimate
1.53Next Dividend Ex-DateN/A
Dividend Yield1.02%
Share Statistics
EPS (TTM)4.13
Shares Outstanding190,737,690
10 Day Avg. Volume0
30 Day Avg. Volume0
Financial Highlights & Ratios
PEG Ratio-1.26
Price to Book (P/B)1.40
Price to Sales (P/S)2.16
P/FCF Ratio12.09
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
CHF86.11Price Target Upside9.69% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering18
EPS Forecast (FY)6.92
Revenue Forecast (FY)CHF6.97B
Bulls Say, Bears Say
Bulls Say
Cash Generation StrengthZimmer Biomet's free cash flow outpacing net income and meaningful YoY FCF and operating cash flow gains provide durable financial flexibility. Strong cash conversion supports continued R&D, capex, debt servicing, and sizable buybacks without depending on volatile external funding.
Product & Robotics AdoptionRapid adoption of new hip implants and enabling tools demonstrates durable competitive advantage in core reconstructive markets. High take‑rates for Z1 and HAMMR, plus outperformance in robotics and tech, should sustain mix improvement, recurring procedure-based consumables, and pricing power over time.
Expanded Liquidity Via Credit LinesFresh multi-year and near-term revolvers increase financial flexibility and support strategic optionality. The facilities lower refinancing risk, preserve capacity for acquisitions or cyclical investment, and provide a buffer that strengthens balance sheet resilience through multi-quarter operational cycles.
Bears Say
Margin Pressure From InvestmentsMaterial margin compression driven by higher manufacturing and commercial investments is a structural headwind to profitability. If sustained, lower operating margins can reduce reinvestment capacity, weaken returns on capital, and compress long‑term free cash flow generation versus peers.
Pricing Erosion & Reimbursement RiskOngoing pricing pressure and potential reimbursement changes create a persistent revenue and margin risk in implant markets. Structural erosion of price realization limits margin sustainability, forces higher volume dependency for growth, and increases sensitivity to cost inflation and payor policy shifts.
Knee Segment And China WeaknessStagnant knee performance and significant China weakness create durable revenue headwinds in key markets. Knee is a core, high‑margin franchise; prolonged softness or slower recovery in China and other emerging markets can reduce growth runway and complicate global commercial leverage.
Zimmer Biomet Holdings News
ZBH FAQ
What was Zimmer Biomet Holdings’s price range in the past 12 months?
Zimmer Biomet Holdings lowest stock price was CHF62.50 and its highest was CHF119.00 in the past 12 months.
What is Zimmer Biomet Holdings’s market cap?
Zimmer Biomet Holdings’s market cap is CHF15.21B.
When is Zimmer Biomet Holdings’s upcoming earnings report date?
Zimmer Biomet Holdings’s upcoming earnings report date is Nov 04, 2026 which is in 76 days.
How were Zimmer Biomet Holdings’s earnings last quarter?
Zimmer Biomet Holdings released its earnings results on Aug 05, 2026. The company reported CHF1.679 earnings per share for the quarter, beating the consensus estimate of CHF1.63 by CHF0.049.
Is Zimmer Biomet Holdings overvalued?
According to Wall Street analysts Zimmer Biomet Holdings’s price is currently Undervalued.
Does Zimmer Biomet Holdings pay dividends?
Zimmer Biomet Holdings pays a Quarterly dividend of CHF0.195 which represents an annual dividend yield of 1.02%. See more information on Zimmer Biomet Holdings dividends here
What is Zimmer Biomet Holdings’s EPS estimate?
Zimmer Biomet Holdings’s EPS estimate is 1.53.
How many shares outstanding does Zimmer Biomet Holdings have?
Zimmer Biomet Holdings has 190,737,690 shares outstanding.
What happened to Zimmer Biomet Holdings’s price movement after its last earnings report?
Zimmer Biomet Holdings reported an EPS of CHF1.679 in its last earnings report, beating expectations of CHF1.63. Following the earnings report the stock price went up 0.645%.
Which hedge fund is a major shareholder of Zimmer Biomet Holdings?
Currently, no hedge funds are holding shares in CH:ZBH
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Zimmer Biomet Holdings Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
CHF86.11 (9.69% Upside)
CHF86.11 (9.69% Upside)
Blogger Sentiment
Bullish
CH:ZBH Sentiment 71%
Sector Average 61%
Sector Average 61%
Insider Transactions
Sold Shares
Worth CHF335.4K over
the Last 3 Months
the Last 3 Months
News Sentiment
Very Bullish
Bullish news 100%
Bearish news 0%
Bearish news 0%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-4.70%
12-Months-Change
Fundamentals
Return on Equity
1.02%
Trailing 12-Months
Asset Growth
-0.29%
Trailing 12-Months
Company Description
Zimmer Biomet Holdings
Zimmer Biomet Holdings, Inc. engages in the design, manufacture, and marketing of orthopedic reconstructive products. The firm also offers sports medicine, biologics, extremities, and trauma products, spine, craniomaxillofacial, and thoracic products, office-based technologies, dental implants, and related surgical products. It operates through the following geographical segments: Americas, Europe Middle East and Africa, and Asia Pacific. The Americas segment consists of the U.S. and includes other North, Central and South American markets. The Europe Middle East and Africa segment includes France, Germany, Italy, Spain, and the United Kingdom. The Asia Pacific segment refers to the key markets such as Japan, China, Australia, New Zealand, Korea, Taiwan, India, Thailand, Singapore, Hong Kong, and Malaysia. The company was founded by Justin O. Zimmer in 1927 and is headquartered in Warsaw, IN.
ZBH Earnings Call
Q2 2026
0:00 / 0:00
Earnings Call Sentiment|Positive
The call conveyed multiple strong operational and financial positives — revenue beat, raised guidance, robust cash generation, rapid technology and hip product adoption, successful Paragon integration and a sizable buyback — while acknowledging near-term headwinds including margin pressure from investment and manufacturing costs, pricing erosion risk, weakness in knees and China, and some supply constraints. Management framed 2026 as a transitional year with confidence that investments and go-to-market changes will improve execution and performance into 2027.View all CH:ZBH earnings summariesZBH Net sales Breakdown
40.36% Knees
25.43% Hips
26.12% S.E.T
8.09% Technology & Data, Bone Cement and Surgical

ZBH Stock 12 Month Forecast
Average Price Target
CHF86.11
▲(9.69% Upside)
Technical Analysis
Boston Scientific
―
Edwards Lifesciences
―
Medtronic
―
Smith & Nephew Snats
―
Stryker
―









